ReviewNature reviews. Immunology2026
Immunogenic cell death and tertiary lymphoid structures: bridging tumour cell death and immune organization.
Review in Nature reviews. Immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recent studies suggest that the formation of tertiary lymphoid structures (TLSs) could be associated with better survival from certain cancers. In this Perspective, we propose that immunogenic cell death (ICD) can act as an upstream organizer of tumour-associated TLSs by coordinating vascular, stromal and immune reprogramming in the tumour microenvironment. ICD leads to the release of tumour antigens and damage-associated molecular patterns that activate innate pathways, such as cGAS-STING signalling, in dendritic cells, myeloid cells, endothelial cells and stromal fibroblasts. These activated cells release type I interferons, TNF and chemokines, such as CCL19, CCL21 and CXCL13, that promote endothelial cell activation and the differentiation of high endothelial venule-like structures. This enables the recruitment of naive and memory lymphocytes and the emergence of perivascular T cell-dendritic cell aggregates, which can form the basis of TLSs. Full structural maturation of TLSs, with segregated B cell and T cell zones, follicular dendritic cell networks and germinal centres, appears to require additional lymphotoxin β receptor (LTβR)-dependent stromal reprogramming. Together, this suggests a two-step model in which ICD first seeds inflammatory vascular niches and then, through LTβR-mediated tissue organization, supports the development of functional TLSs.
Identifiers
42749753What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.